Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Context Therapeutics ( (CNTX) ) is now available.
Context Therapeutics Inc. has amended its Sales Agreement with Leerink Partners LLC to increase the aggregate offering amount of its common stock shares to $75 million, excluding shares previously sold. As of October 24, 2025, the company had sold shares worth approximately $15 million under a prior prospectus. The amendment allows for further sales under a new registration statement, with proceeds intended for research, development, and general corporate purposes. The agreement includes customary terms and allows termination by either party with notice.
The most recent analyst rating on (CNTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.
Spark’s Take on CNTX Stock
According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.
Context Therapeutics has significant financial challenges, with no revenue and consistent losses, heavily weighing down its overall score. Technical analysis shows neutral market momentum, while valuation metrics highlight unprofitability. However, the recent initiation of a Phase 1 trial offers some hope for future growth. Collectively, these factors result in a low overall stock score, reflecting the company’s current financial instability and speculative potential.
To see Spark’s full report on CNTX stock, click here.
More about Context Therapeutics
Average Trading Volume: 268,881
Technical Sentiment Signal: Buy
Current Market Cap: $108.5M
See more insights into CNTX stock on TipRanks’ Stock Analysis page.